Raymond Douglas, MD, PhD, discusses trends in treatment of thyroid eye disease and how the approval of teprotumumab has impacted the prospect of treating the condition.
This episode of the Endocrine Outlook features a conversation with Raymond Douglas, MD, PhD, of Cedars-Sinai Medical Center. In the interview, Douglas discusses and offers perspective on a recent study he led examining trends in treatment of active, moderate-to-severe thyroid eye disease in the United States.
With data collection ending in 2018, the study does not reflect changes in treatment that have come after the approval of teprotumumab (Tepezza) but Douglas asserts it offers an accurate overview of therapies used to control symptoms from the disease. Later in the interview, Douglas reflects on how the approval of teprotumumab has impacted treatment algorithms and how the ongoing pandemic has impacted the lives of patients with thyroid eye disease.
This study, “Trends in treatment of active, moderate-to-severe thyroid eye disease in the United States,” was published in the Journal of the Endocrine Society.